A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies
This research study is testing a new medication called ianalumab for adults who have a blood condition known as Primary Immune Thrombocytopenia (ITP). ITP causes low platelet counts, which help your blood clot. We are particularly interested in people whose ITP hasn't improved enough with at least two other types of treatment, including a steroid and a TPO-RA. The main goals are to find out if ianalumab is effective in raising platelet counts, how safe it is, and if people can take it without too many side effects. Participants will receive the medication, and their health will be closely monitored for around two years to understand the long-term effects.
En un coup d'œil
De quoi parle cette étude ?
This study is for adults who have a condition called Primary Immune Thrombocytopenia, or ITP for short. ITP is a blood disorder where your body's immune system mistakenly attacks and destroys its own platelets. Platelets are tiny blood cells that help your blood clot, so low platelet counts can lead to bruising and bleeding problems.
You might be interested in this study if you've already tried at least two other types of ITP treatments, such as certain steroids and a medication called a TPO-RA, but your platelet counts are still low (under 30 G/L) and your doctor thinks you need more treatment. The medication being tested is called ianalumab. We want to understand if it can help improve platelet counts, if it's safe to use, and if people find it easy to tolerate.
This is a 'Phase 2' study, which means we're evaluating the medication in a small group of people to see if it works and to get more information about its safety before potentially moving to larger studies. Understanding if ianalumab can help people who haven't responded well to other treatments is very important for finding new ways to manage ITP.
Points clés
- This study evaluates ianalumab for adults with ITP.
- It's for those whose ITP hasn't responded to at least two prior treatments.
- The study will check if ianalumab is effective and safe.
- Participants will be closely monitored for around two years.
- Vous pouvez vous retirer de l'étude à tout moment.
- Talk to your doctor if you think this study might be right for you.
Qui peut être éligible ?
You might be able to join this study if you are 18 years old or older and have been diagnosed with primary ITP. You must have already tried at least two different treatments for your ITP, including a steroid and a TPO-RA, and your platelet count is still low (below 30 G/L) and your doctor believes you need treatment. You will need to agree to take part by signing an informed consent form.
There are also some reasons why you might not be able to join. For example, if your low platelet count is due to another medical condition (secondary thrombocytopenia) or if you've had certain treatments very recently, like a blood transfusion or some types of strong immunosuppressant medicines. Also, if you've had your spleen removed, you won't be able to participate. Your medical team will check all these details carefully.
Cet étude pourrait-elle vous convenir ?
Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.
- Avez-vous 18 ans ou plus ?
- Have you been diagnosed with Primary ITP?
- Have you already tried at least two ITP treatments (like a steroid and a TPO-RA)?
- Is your platelet count currently low (below 30 G/L) and your doctor thinks you need treatment?
- Have you NOT had your spleen removed?
- Have you NOT had treatments like blood transfusions or certain strong immunosuppressants very recently?
En quoi consiste la participation ?
If you decide to take part, the study will start with a screening period of up to two weeks. During this time, doctors will do tests to make sure you're a good fit for the study. If you qualify, you will receive the study medicine, ianalumab, at the same dose as other participants.
After you start the medicine, you'll have regular check-ups to see how well the treatment is working and to monitor for any side effects. These check-ups will continue for a main assessment period. After this, if your platelet count is stable and you're not needing other ITP treatments, your health will continue to be monitored for safety and effectiveness. Some people who initially respond well but later see their platelet counts drop might be offered a second course of ianalumab. The study will follow all participants for up to two years after their last dose of ianalumab, meaning the total time in the study could be around two years or more.
Risques et avantages potentiels
Locations (24)
- Hôpital Général du MassachusettsCode postal vérifiéBoston, États-Unis
- Beth Israel Deaconess Med CenterCode postal vérifiéBoston, États-Unis
- Site d'Investigation NovartisVille uniquementCABA, Argentina
- Site d'Investigation NovartisCode postal vérifiéGarran, Australia
- Site d'Investigation NovartisCode postal vérifiéMelbourne, Australie
- Site d'Investigation NovartisCode postal vérifiéWuhan, Chine
- Site d'Investigation NovartisCode postal vérifiéPékin, Chine
- Site d'Investigation NovartisCode postal vérifiéJinan, China
- Site d'Investigation NovartisCode postal vérifiéToulouse, France
- Site d'Investigation NovartisCode postal vérifiéDresde, Allemagne
- Site d'Investigation NovartisCode postal vérifiéJena, Allemagne
- Site d'Investigation NovartisCode postal vérifiéGiessen, Germany
Questions fréquentes
What is ITP?
ITP stands for Primary Immune Thrombocytopenia. It's a condition where your body's immune system attacks and destroys its own platelets, leading to a low platelet count and a higher risk of bleeding.
What is ianalumab?
Ianalumab is the new medicine being tested in this study. It's hoped to help increase platelet counts in people with ITP, especially those who haven't responded well to other treatments.
What does 'Phase 2 study' mean?
A Phase 2 study means that we are testing the new medicine in a small group of people to see if it works and to gather more information on its safety, before potentially moving on to larger studies.
Combien de temps vais-je participer à l'étude ?
You could be in the study for up to two years or possibly longer, depending on whether you receive a second course of treatment and when you had your last dose of ianalumab.
Puis-je arrêter de participer si je le souhaite ?
Yes, absolutely. Taking part is entirely your choice, and you can withdraw from the study at any time without having to give a reason, and it won't affect your future medical care.
Comment en savoir plus
Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.
Discussion
Discussion communautaire
Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.